News
LenioBio launches ALiCE® HTPE, driving next-generation Antibody Discovery
LenioBio is pleased to unveil ALiCE® for High-Throughput Protein Expression (ALiCE® HTPE), the first eukaryotic cell-free expression platform specifically engineered for rapid antibody discovery and screening
LenioBio partners with Avantor, bringing cutting edge cell-free protein expression technology to researchers across Europe
LenioBio is proud to announce that it has been awarded the prestigious STEP Seal by the European Commission as part of its submission to the EU4Health funding call.
LenioBio Earns Prestigious EU STEP Seal: A Signal of Excellence for Investors
LenioBio is proud to announce that it has been awarded the prestigious STEP Seal by the European Commission as part of its submission to the EU4Health funding call.
LenioBio Collaborates with ReciBioPharm to Scale Up ALiCE® Technology and Expedite Vaccine Production
LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a collaboration with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale up protein manufacturing capabilities and expedite vaccine production.
Touchlight and LenioBio collaborate to accelerate development of protein therapeutics for pandemic response
LenioBio and Touchlight announce supply agreement to leverage rapid enzymatic doggybone DNA to accelerate vaccine development and manufacture in the context of LenioBio's CEPI grant.
Labscoop and LenioBio Announce Strategic Partnership to Enhance Access of Scalable Cell-Free Protein Synthesis Technology Across North America.
Labscoop LLC, announce a strategic partnership to bring LenioBio’s line of cutting-edge products and services to Labscoop Marketplace users and the North American market more broadly.
Plant-Based ALiCE® Technology Could Shave Weeks Off Vaccine Production
LenioBio GmbH has received CEPI funding of up to US $2 million to provide preclinical proof-of-concept that their commercially available, plant-based, and cell-free technology can produce proteins for use in clinical trials testing vaccines against epidemic and pandemic threats in 20-40 days.
LenioBio Appoints CTO and CCO to Spearhead Growth and Innovation
LenioBio today announced the appointments of Kathrin Knauf as Chief Technology Officer and Malene Linderoth as Chief Commercial Officer.
LenioBio appoints Hugh Watson as Chief Financial Officer
LenioBio appoints Hugh Watson as Chief Financial Officer as of January 1st, 2024. Hugh brings with him a wealth of experiene and strategic financial insight.
LenioBio announces appointment of Professor Daniel Bracewell to its Scientific Advisory Board.
Prof. Bracewell is appointed member of LenioBio's Scientific Advisory Board.
LenioBio announces appointment of new Chief Business Officer to Leadership Team
Jasper Levink joined LenioBio in January 2022 as Lead of the Business Unit...
LenioBio reaches industrial-scale with its high-yield eukaryotic platform for cell-free protein synthesis.
LenioBio reaches industrial-scale with its high-yield eukaryotic platform for cell-free protein synthesis.
A breakthrough in biopharmaceutical protein production; LenioBio announces a new proprietary cell line devoid of plant glycans.
LenioBio generated a novel plant glycan knockout cell line that will increase the versatility and flexibility...
LenioBio awarded prestigious Eurostars grant
LenioBio GmbH announced today that the company has been awarded a grant...
LenioBio closes its Series-A Extension round and strengthens its Board of Directors.
LenioBio closed its Series-A Extension round with a total investment volume of €11.5 million and strengtheneds its board of directors.
LenioBio Wins Prestigious Horizon 2020 SME/2 Grant
The company has been awarded a grant to accelerate the scale-up of its proprietary protein expression platform ALiCE.
LenioBio Announces a Scientific Advisory Board Composed of Experts within the Field of Biotechnology
New Scientific Advisory Board composed of experts within the field of Biotechnology.
LenioBio GmbH and Fraunhofer IME to Advance Novel Protein Discoveries through a License Agreement
LenioBio GmbH and Fraunhofer IME to Advance Novel Protein Discoveries through a License Agreement
Protein Science to Advance through LenioBio and Dow AgroSciences License Agreement
Protein Science to Advance through LenioBio and Dow AgroSciences License Agreement
LenioBio accesses tailor-made business opportunities
Companies supported under the European Innovation Council had the opportunity to accelerate their business...